Aurobindo Pharma completes acquisition of select Western European Businesses of Actavis

02 Apr 2014 Evaluate

Aurobindo Pharma has completed the acquisition of certain commercial operations in Western Europe from Actavis plc. The agreement to acquire the Actavis operations was announced in January 2014. The company acquired personnel, commercial infrastructure, products, marketing authorizations and dossier licence rights in seven European countries. Actavis and Aurobindo have also entered into a long term commercial and supply arrangement.

Following receipt of clearances from competent authorities, Aurobindo now intends to combine the strength of both enterprises (including its vertically integrated platform and existing commercial infrastructure) in these markets and to identify and maximize all opportunities to improve performance.

The acquisition will make the company one of the leading Indian pharmaceutical companies in Europe. The acquisition will also enable Aurobindo to achieve critical mass in Western Europe with a top 10 position in several key markets.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1187.20 -11.80 (-0.98%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×